Breast Cancer Clinical Trial
Official title:
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug.
Lapatinib may also stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Giving lapatinib together with paclitaxel may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when
given together with paclitaxel in treating patients with advanced solid tumors.
Status | Completed |
Enrollment | 28 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor, including the following tumor types: - Breast cancer - Non-small cell lung cancer - Prostate cancer - Bladder cancer - Gastroesophageal junction cancer - Ovarian cancer - Germ cell tumor - Advanced or metastatic disease - No effective curative therapy exists - Evaluable disease - Measurable disease not required - Bone-only disease allowed - No progressing brain metastases PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy > 3 months - Absolute neutrophil count = 1,500/mm^3 - Hemoglobin = 9.0 g/dL - Platelet count = 100,000/mm^3 - Bilirubin normal - AST/ALT = 2.5 times upper limit of normal - Creatinine normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No serious intercurrent medical or psychiatric illness - No serious active infection - No gastrointestinal tract disease that would impair a patient's ability to take oral medication - No history of significant cardiac disease, including any of the following: - Congestive heart failure - Symptomatic cardiac arrhythmias - Unstable angina - No pre-existing peripheral neuropathy = 2 PRIOR CONCURRENT THERAPY: - Any number of prior therapies allowed - Prior paclitaxel, tyrosine kinase inhibitor therapy, or endothelial growth factor inhibitors allowed - At least 14 days since prior and no concurrent CYP3A4 inducers or herbal or dietary supplements - At least 7 days since prior and no concurrent CYP3A4 inhibitors - At least 6 months since prior and no concurrent amiodarone - More than 1 month since prior chemotherapy, radiotherapy, hormonal therapy, or investigational anticancer agents - Concurrent continued use of gonadal suppression agents (i.e., goserelin acetate or leuprolide acetate) allowed - No antacids 1 hour before and after study drug administration - No concurrent retinoids - No concurrent hormonal anticancer agent - No other concurrent anticancer chemotherapy or investigational anticancer agents |
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Cancer Institute (NCI) |
United States,
Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose (MTD) of lapatinib in course 1 | estimated to be 12 weeks | Yes | |
Secondary | Toxicity | up to 12 weeks | Yes | |
Secondary | Anti-tumor efficacy and safety every 8 weeks | until disease progression estimated to be 12 weeks | Yes | |
Secondary | Pharmacokinetics during the first 2 weeks of treatment | 2 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |